Keyword: Ozempic (semaglutide)
As Novo Nordisk’s highly anticipated semaglutide nears the market, the company has a big decision to make: How will it price the product?
Novo Nordisk expects basal insulin prices to sink even further next year—but that shouldn’t surprise investors too much, the company’s CEO says.
Novo Nordisk debuted its first DTC campaign for Type 2 diabetes drug Ozempic this week, setting the promotional stage for its aspiring blockbuster.
Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.
Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another.
Novo Nordisk’s next big hope is an oral version of its new launch, Ozempic (semaglutide), and the data in its favor just keeps piling up.
Once it wins approval, Novo Nordisk’s semaglutide will go up against some stiff competition. But the drugmaker just showed it can take the heat.
A Bernstein analyst said media reports "misrepresent the situation."
A leading position in insulin, combined with new launches like GLP1 drug Victoza, could help Novo grow to DKK19 billion in China by 2025.
In a phase 3 study, Novo said oral semaglutide helped diabetes patients manage their blood sugar levels better than Jardiance.
